2023 World Conference on Lung Cancer (Posters)-EP12.01. Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations

EP12.01. Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations - PDF(Abstract)

Back to course

Pdf Summary

This document is a case report presented at the WCLC 2023 conference. The report discusses the exceptional response of a patient with advanced non-small cell lung cancer (NSCLC) to the targeted therapy drug Aumolertinib. The patient had rare EGFR exon20 mutations (V774M and S768I).<br /><br />The introduction section highlights that EGFR exon20 alterations are typically difficult to treat, as they are less sensitive to current EGFR-TKIs or chemotherapy. The second-generation EGFR-TKI afatinib has shown some effectiveness in treating complex rare EGFR mutations, but with more adverse effects. Aumolertinib, a novel third-generation EGFR-TKI, is presented as a potential better option in terms of safety and efficacy.<br /><br />The case report describes a 52-year-old woman with stage IIIa NSCLC, who underwent surgery but had ineffective results due to mediastinal lymph node and pleural metastases. The patient was then treated with Aumolertinib from April 2020, and a significant tumor shrinkage was observed after one month of treatment. However, brain metastases were later detected, and the patient underwent whole-brain radiotherapy. Following radiotherapy, disease progression was observed in both the lung and brain. Aumolertinib in combination with the anti-angiogenic drug anlotinib resulted in stable disease. The patient continued the treatment until her death in July 2022. The overall survival of the patient was 28 months.<br /><br />The conclusion of the case report suggests that EGFR V774M/S768I mutations can be activating mutation complexes, and treatment with Aumolertinib monotherapy or in combination with anti-angiogenic drugs can achieve significant clinical benefits for patients with these complex mutations. This report provides valuable insights into potential treatment regimens for patients with EGFR exon20 mutations.<br /><br />In summary, this case report highlights the exceptional response of a patient with rare EGFR exon20 mutations to Aumolertinib treatment. The findings provide meaningful insights into potential treatment options for patients with similar complex mutations.

Asset Subtitle

Tao Tao

Meta Tag

Speaker Tao Tao

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023 conference

case report

NSCLC

Aumolertinib

EGFR exon20 mutations

third-generation EGFR-TKI

tumor shrinkage

brain metastases

anti-angiogenic drug

treatment regimens